Kazazian Asset Management’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Kazazian Asset Management’s Portfolio BIVV Stock Details BIVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-5,201	Closed	-$280K	–	92
2017 Q4	$280K	Buy	5,201 +538	+12%	+$29.4K	0.29%	68
2017 Q3	$266K	Buy	+4,663	New	+$273K	0.33%	57
2017 Q2	–	Sell	-5,598	Closed	-$305K	–	59
2017 Q1	$305K	Buy	+5,598	New	+$276K	0.42%	30

Other funds holding BIVV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ACS

Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Kazazian Asset Management's BIVV Position: Q1 2018 in Review

Kazazian Asset Management sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 5,201 shares — an estimated $280K sold.

Kazazian Asset Management first reported a position in BIVV in Q1 2017 and held it in 3 quarters. The position peaked at $305K in Q1 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

Kazazian Asset Management reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Kazazian Asset Management sold 5,201 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $280K.
Kazazian Asset Management first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 3 quarters.
Kazazian Asset Management's Bioverativ Inc. Common Stock position peaked at $305K in Q1 2017.
2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Kazazian Asset Management's 13F filing for Q1 2018, filed 15 May 2018.